Gut inflammation and axial spondyloarthritis –SPARTAKUS cohor

The relationship between gut inflammation and axial spondyloarthritis (axSpA) has been extensively studied, and the SPARTAKUS cohort plays a key role in advancing our understanding of this association. Below is a detailed explanation of the gut-joint hypothesis, the influence of gut inflammation on joint inflammation, and the significance of the SPARTAKUS cohort in studying these phenomena.

---

### **Gut-Joint Hypothesis**

The gut-joint hypothesis posits that inflammation in the gut can influence inflammation in distant sites like the spine and joints, contributing to the development and progression of diseases such as axial spondyloarthritis (axSpA). This connection is thought to occur through several mechanisms:

1. **Immune System Crosstalk**:

• The gut is a central hub for immune system regulation. Dysbiosis (imbalance in gut microbiota) or subclinical gut inflammation can lead to aberrant activation of immune pathways, particularly the IL-23/IL-17 axis, which is implicated in axSpA pathogenesis.
• These inflammatory cytokines can travel through the bloodstream and contribute to systemic inflammation, including inflammation in the joints and spine.

2. **Molecular Mimicry**:

• Certain gut microbial antigens may resemble self-antigens, leading to an autoimmune response that targets both the gut and musculoskeletal system.

3. **Leaky Gut Syndrome**:

• Gut inflammation can result in increased intestinal permeability ("leaky gut"), allowing microbial products like lipopolysaccharides (LPS) to enter the bloodstream and trigger systemic inflammation.

4. **Shared Genetic Susceptibility**:

• Genetic factors like HLA-B27, which are strongly associated with axSpA, may also predispose individuals to gut inflammation, creating a bidirectional relationship between gut health and musculoskeletal disease.

---

### **How Gut Inflammation Influences Joint Inflammation**

Gut inflammation, as measured by biomarkers like fecal calprotectin (F-calprotectin), has been shown to correlate with joint and spinal inflammation in axSpA. Key mechanisms include:

1. **Cytokine Pathways**:

• Elevated gut inflammation activates pro-inflammatory cytokines such as IL-17, IL-23, and TNF-alpha, which are directly involved in the chronic inflammation seen in axSpA.
• These cytokines promote the recruitment of immune cells to the joints and spine, leading to inflammation and structural damage.

2. **Systemic Inflammatory Burden**:

• Persistent gut inflammation contributes to an overall heightened inflammatory state, which can exacerbate joint and spinal damage over time.

3. **Subclinical Gut Inflammation**:

• Even in the absence of overt symptoms of inflammatory bowel disease (IBD), subclinical gut inflammation (detected via elevated F-calprotectin) can influence musculoskeletal disease severity in axSpA patients.

4. **Radiographic Progression**:

• Studies, including the SPARTAKUS cohort, have demonstrated that elevated F-calprotectin levels are independently associated with greater structural spinal damage, as measured by the modified Stoke Ankylosing Spondylitis Spinal Score (mSASSS). This suggests that gut inflammation contributes to long-term radiographic progression in axSpA.

---

### **SPARTAKUS Cohort and Its Importance**

The SPARTAKUS cohort is a population-based study conducted in southern Sweden, involving 228 patients with well-characterized axial spondyloarthritis (axSpA). Its primary goal is to investigate the underlying mechanisms, clinical characteristics, and progression of axSpA, with a particular focus on gut inflammation.

#### **Key Features of the SPARTAKUS Cohort**:

1. **Large Sample Size**:

• The cohort includes 228 patients, divided into non-radiographic axSpA (nr-axSpA, n=76) and radiographic axSpA (r-axSpA, n=152) groups. This allows researchers to explore disease differences across varying severity levels.

2. **Comprehensive Data Collection**:

• Participants are well-characterized, with detailed information on demographics, genetic markers (e.g., HLA-B27), disease activity scores (ASDAS, BASDAI), imaging (mSASSS), and biomarkers like fecal calprotectin and C-reactive protein (CRP).

3. **Focus on Gut Inflammation**:

• The cohort specifically examines the role of gut inflammation in axSpA progression, using F-calprotectin as a biomarker to assess subclinical intestinal inflammation.

4. **Robust Statistical Analysis**:

• The study adjusts for confounding factors such as sex, smoking, NSAID use, TNF inhibitor therapy, and comorbidities like inflammatory bowel disease (IBD), ensuring the reliability of its findings.

#### **Significance of SPARTAKUS Cohort Findings**:

1. **Gut-Spine Connection**:

• The study provides strong evidence for the gut-joint axis hypothesis, showing that elevated F-calprotectin levels are independently associated with greater structural spinal damage in axSpA.

2. **Radiographic Progression**:

• Patients with higher F-calprotectin levels consistently exhibit more severe radiographic damage, particularly in the r-axSpA subgroup. This highlights the potential of gut inflammation as a driver of disease progression.

3. **Clinical Correlations**:

• Elevated F-calprotectin levels are also associated with higher CRP levels, longer symptom duration, and higher disease activity scores (ASDAS, BASDAI), reinforcing the role of inflammation in cumulative spinal damage.

4. **IBD Independence**:

• The association between gut inflammation and spinal damage persists even after excluding patients with IBD, suggesting that subclinical gut inflammation alone can contribute to axSpA severity.

5. **Diagnostic and Prognostic Utility**:

• F-calprotectin testing may serve as a non-invasive biomarker for identifying patients at risk of progressive spinal ankylosis, aiding in early intervention and personalized treatment strategies.

6. **Pathophysiological Insights**:

• The study supports the hypothesis that gut inflammation, possibly mediated by the IL-23/IL-17 pathway, plays a central role in axSpA pathogenesis and progression.

---

### **Future Directions**

The SPARTAKUS cohort findings underscore the need for further research into the gut-joint axis in axSpA. Future studies should focus on:

1. **Longitudinal Analysis**:

• Tracking patients over time to determine whether elevated F-calprotectin predicts future radiographic progression.

2. **Intervention Trials**:

• Investigating whether targeting gut inflammation (e.g., through dietary modification, probiotics, or anti-inflammatory therapies) can alter spinal outcomes in axSpA.

3. **Advanced Imaging**:

• Incorporating spinal MRI data to directly assess concurrent inflammatory activity and structural damage.

4. **Mechanistic Studies**:

• Exploring the molecular pathways linking gut and joint inflammation, particularly the role of microbiota and cytokines like IL-23 and IL-17.

---

### **Conclusion**

The SPARTAKUS cohort has provided compelling evidence that gut inflammation, as measured by fecal calprotectin, is independently associated with greater structural spinal damage in axial spondyloarthritis. These findings highlight the gut’s central role in disease pathogenesis and progression, supporting the gut-joint hypothesis. F-calprotectin testing may emerge as a valuable tool for predicting radiographic progression and guiding personalized treatment strategies, emphasizing the need for further research into the gut-joint axis in axSpA.